

Start	End	Topic	Speakers
11:30	11:40	Welcome and Introduction	Montserrat Espuña Pons
11:40	12:00	Is surgery always the best option for treatment of POP?	Cristina Ros Cerro
12:00	12:20	If we operate, should we leave the uterus in or out?	Hugo van Eijndhoven
12:20	12:40	If we save the uterus, which technique would be preferred?	Kirsten Kluivers
12:40	12:55	Discussion	Montserrat Espuña Pons Kirsten Kluivers Hugo van Eijndhoven Cristina Ros Cerro
12:55	13:00	Conclusion	Montserrat Espuña Pons

### **Aims of Workshop**

Treatment of Pelvic Organ Prolapse (POP) has long been subject to surgeons' preference. Removal of the uterus has long been the standard surgical option for symptomatic POP. Is that the best option? Is surgery really necessary? What alternatives do we have? What evidence is available for these choices? Are patient's own perspectives taken into account in what we offer them as treatment?

### **Learning Objectives**

1. How do patient reported improvements compare between surgery and pessary?
2. Removing or saving the uterus? Which is best from a patient's perspective?
3. What evidence do we have for the choice between uterus-sparing techniques?

### **Target Audience**

Urogynaecology and Female & Functional Urology, Conservative Management

### **Advanced/Basic**

Intermediate

## **IUGA Workshop - How Do We Treat Pelvic Organ Prolapse in 2024?**

Chair: Montse ESPUÑA-PONS - Speakers: *Hugo van EIJDJOVEN*, *Kristen KLUIVERS*, Cristina ROS

Times are changing and so is the treatment of pelvic organ prolapse (POP). Better understanding of women's preferences and shared-decision making have changed the attitude of (uro)gynecologists towards this subject. In this workshop we highlight and discuss the evolution of both conservative and surgical treatment over the last decade.

### **CONSERVATIVE TREATMENT OF PELVIC ORGAN PROLAPSE.**

*Cristina ROS*

When faced with a woman with a POP, different therapeutic options should be offered: expectant management if the POP is asymptomatic, lifestyle interventions, pelvic floor muscle training (PFMT), pessary or surgery.

#### **1. PELVIC FLOOR MUSCLE TRAINING**

Nowadays, there is good evidence that PFMT is effective in reducing POP symptoms and improving POP stage, in women with POP stage 1, 2 and 3. However, there are no evidence of improvement after perioperative PFMT (pre- or post-surgery).

Although there is scarce data about long-term effect of PFMT on POP, it appears that there are no adverse effects or complications related to PFMT.

Nevertheless, it is essential to provide proper information to women on why and how to perform PFMT to improve pelvic floor morphology and POP. In addition, the staff should teach PFM contraction technique, assess if it is correct and offer periodic visits for at least 6 months.

A strength training regimen includes 3 sets of 8-12 close to maximum contractions at least 3-4 times/week during at least 4 months, with a PFMT maintenance including 8-12 contractions 1-2 times/week.

In conclusion, PFMT could be recommended as the first-line treatment for POP in general female population. It is effective and safe but needs instruction and supervision (Bo et al. 2022)

## 2. PESSARY

Among women with POP, half prefer surgery whereas one third prefer pessary. However, up to 14% of gynaecologists never inform their patients about pessaries.

The conclusion of a multicentric noninferiority randomized clinical trial (RCT) was that, among patients with symptomatic POP, an initial strategy of pessary, compared with surgery, did not show non-inferiority regarding patient-reported improvement at 24 months. Subjective improvement was reported by 76% of women in the pessary group and 81.5% in the surgery group ( $p=0.16$ ). Nevertheless, cross-over from pessary to surgery occurred among 54% participants, mainly due to pessary expulsion. The most common adverse effect in the pessary group was discomfort (42.7%) (van der Vaart et al. 2022).

Women with symptomatic POP who refused to participate in the RCT due to preferences in treatment choice (surgery or pessary), were included in an observational cohort study. Both groups showed a significant reduction in bothersome POP symptoms compared with baseline. However, significantly more women in the surgery group reported a subjective improvement after 24 months (83.8% vs 74.4%). In this cohort, up to 30% of women stopped the pessary at 24 months, and 23.6% switched to surgery, due to pessary expulsion or insufficient symptom relief. Finally, comparing both population, women who chose surgery were younger, premenopausal, with higher body mass index and more severe subjective symptoms of POP. (van der Vaart et al. 2022)

In a cohort of women aged 75 or older, three quarters opted for a pessary. However, two-third of these ended up having surgery (Dykes N et al. 2023).

When the chosen treatment is a pessary, an initial visit should be performed, offering supportive or occlusive pessaries. Pessary fitting is successful if the patient feels comfortable with the pessary in situ without expulsion. In case of pessary expulsion, a trial of another type/size should be offered. If it is possible, self-management is the best option, with a personal cleaning frequency. If it is not possible, visits should be scheduled at least every 4 months.

The most common pessary complications are: vaginal discharge or bleeding, vaginal erosions, pessary expulsion, discomfort or urinary incontinence. Risk factors for pessary failure are younger age, previous hysterectomy and increasing parity.

In conclusion, pessary should be offered as a first-line option among women with symptomatic POP, with significant reduction in bothersome POP symptoms. However, the chance of significant improvement is higher following surgery. Patients needs to be advised of the possible

complications, as discomfort, vaginal discharge, erosion or expulsion, and the high chance of requiring surgery at a later stage, both in young women or over 75 years old.

## REFERENCES

Bø K, Anglès-Acedo S, Batra A, Brækken IH, Chan YL, Jorge CH, Kruger J, Yadav M, Dumoulin C. International urogynecology consultation chapter 3 committee 2; conservative treatment of patient with pelvic organ prolapse: Pelvic floor muscle training. *Int Urogynecol J*. 2022 Oct;33(10):2633-2667.

van der Vaart LR, Vollebregt A, Milani AL, Lagro-Janssen AL, Duijnhoven RG, Roovers JWR, van der Vaart CH. Effect of Pessary vs Surgery on Patient-Reported Improvement in Patients With Symptomatic Pelvic Organ Prolapse: A Randomized Clinical Trial. *JAMA*. 2022 Dec 20;328(23):2312-2323.

van der Vaart LR, Vollebregt A, Milani AL, Lagro-Janssen AL, Duijnhoven RG, Roovers JP, Van der Vaart CH. Pessary or surgery for a symptomatic pelvic organ prolapse: the PEOPLE study, a multicentre prospective cohort study. *BJOG*. 2022 Apr;129(5):820-829.

Dykes N, Lim YN, Zilberlicht A, Dwyer PL. Are older patients with prolapse likely to continue pessary use? A retrospective observational study. *Int Urogynecol J*. 2023 Dec;34(12):2919-2923.

## SURGICAL TREATMENT OF APICAL PELVIC ORGAN PROLAPSE.

*Kristen KLUIVERS, Hugo van EIJDJOVEN*

The first choice of treatment of POP is conservative treatment, such as lifestyle interventions, pelvic floor physical therapy and pessary treatment as has been discussed in the first part of the workshop. These interventions may lead to reduction of prolapse complaints and might be satisfactory for a large population with mild prolapse complaints. For whom it is not sufficient, several surgical options are available for the treatment of POP depending on the affected site. A vaginal approach is preferred as a first surgical treatment option.

For **uterine descent**, the options can be divided in uterus preserving techniques, such as the Manchester procedure (MP) or the sacrospinous hysteropexy (SSH), or non-preserving techniques such as vaginal hysterectomy with uterosacral ligament suspension (VH). The choice for surgical technique depends on the available evidence, the general health of the women, the severity of the prolapse, the woman's preference and of the surgeon. Worldwide, VH with uterosacral ligament suspension is the most frequently executed operation for the treatment of

uterine descent (Jha et al 2018) . In recent years a upcoming trend towards uterus-preserving surgery has been noticed (Detollenaere et al 2023). Similar or even lower recurrence rates have been shown (Schulten et al 2019). Furthermore, uterus-preserving techniques are often considered to be less-invasive as they are known to have shorter operating time, less blood loss and shorter recovery time. This makes them more appealing and more in line with patient preferences. Husby et al. (2020) showed a decrease of vaginal hysterectomies and an increase of MP and SSH between 2010 and 2016 in Denmark. This is in line with findings from other countries (Madsen et al. 2017, Wu et al. 2012, Zacche et al. 2018).

Uterus removal decreases the risk of additional uterine malignancies or other uterine pathological conditions. However, the rate of these malignant conditions is low (0.8 – 1.1%) and no higher stages at discovery of malignancy have been found (Husby et al. (2022).

The technique of the Manchester procedure is discussed in most detail in the workshop, as this technique is least well known and there is most variation in the performance.

This Manchester procedure is the first reconstructive procedure preserving the uterus and was originally described by Archibald Donald of Manchester, England in 1888 when exploring different conservative prolapse operations for uterine prolapse. Initially the operation was executed by combining anterior and posterior colporrhaphy with a cervical amputation, which was often performed in two separate sittings. This technique was modified by John Fothergill, who combined the earlier two-step procedures into one single operation and included parametrial fixation. Initially the preservation of the uterus was important for potential future childbearing and religiously important, but the pregnancy rates were low and prematurity was a common complication after this procedure. The traditionally Manchester Fothergill procedure consisted of plication and fixation of the cardinal ligaments and cervical amputation. Over the years the Manchester procedure was modified to the procedure as described in the IUGA/ICS Joint report on terminology for surgical procedures to treat POP (2020): the shortening or the amputation of the cervix with preservation of the uterine body and plication of the uterosacral-cardinal ligament complex extra peritoneally caudad to this amputation.

### **Comparison of surgical techniques for the treatment of uterine descent**

Several studies have investigated surgical outcomes after native tissue repair such as MP or SSH versus VH in the treatment of POP. A systematic review and meta-analysis by Kapoor et al. (2017) investigated SSH with VH for uterine descent. There were no statistical significant differences

between the two interventions concerning the effectivity and reoperation rate. Maher et al. conducted a Cochrane review (2016,2023) comparing SSH with VH. In the three studies included, a statistically significant higher rate of recurrence of posterior vaginal wall prolapse after VH was found compared to SSH (18% versus 7%). The SAVE-U trial is a large Dutch RCT comparing SSH with VH. This study showed that the treatment of uterine descent with SSH in comparison with VH with uterosacral ligament suspension was non-inferior after 12 months of follow-up (Detollenaere et al.2015). After 5 years of follow-up, Schulten et al. (2019) showed that SSH had less anatomical recurrences of the apical compartment with bothersome bulge symptoms or repeat surgery compared to VH with uterosacral ligament suspension. Several studies concluded that uterus-preserving surgical techniques such as the MP or SSH have comparable or even better outcomes. A Danish study found the MP to be superior to VH for the treatment of POP concerning the recurrence of POP as well as the costs perspective (Husby et al. 2017, 2018). A large randomized controlled trial comparing SSH with MP has been performed in the Netherlands. Based on the composite outcome of surgical success 2 years, the results support a finding that sacrospinous hysteropexy is inferior to the Manchester procedure (Enklaar et al 2023).

## REFERENCES

Jha S, Cutner A, Moran P. The UK National Prolapse Survey: 10 years on. *International urogynecology journal*. Jun 2018;29(6):795-801.

Detollenaere RJ, den Boon J, Kluivers KB, Vierhout ME, van Eijndhoven HW. Surgical management of pelvic organ prolapse and uterine descent in the Netherlands. *International urogynecology journal*. May 2013;24(5):781-8.

Schulten SFM, Detollenaere RJ, Stekelenburg J, IntHout J, Kluivers KB, van Eijndhoven HWF. Sacrospinous hysteropexy versus vaginal hysterectomy with uterosacral ligament suspension in women with uterine prolapse stage 2 or higher: observational follow-up of a multicentre randomised trial. *BMJ (Clinical research ed)*. Sep 10 2019;366:l5149.

Husby KR, Lose G, Klarskov N. Trends in apical prolapse surgery between 2010 and 2016 in Denmark. *Int Urogynecol J*. 2020 Feb;31(2):321-327. doi:10.1007/s00192-018-3852-7.

Husby KR, Gradel KO, Klarskov N. Endometrial cancer after the Manchester procedure: a nationwide cohort study. *International urogynecology journal*. Apr 13 2022;doi:10.1007/s00192-022-05196-4

Madsen AM, Raker C, Sung VW. Trends in Hysteropexy and Apical Support for Uterovaginal Prolapse in the United States from 2002 to 2012. *Female pelvic medicine & reconstructive surgery*. Nov/Dec 2017;23(6):365-371. doi:10.1097/spv.0000000000000426

Wu MP, Long CY, Huang KH, Chu CC, Liang CC, Tang CH. Changing trends of surgical approaches for uterine prolapse: an 11-year population-based nationwide descriptive study. *International urogynecology journal*. Jul 2012;23(7):865-72. doi:10.1007/s00192-011-1647-1

Zacche MM, Mukhopadhyay S, Giarenis I. Trends in prolapse surgery in England. *International urogynecology journal*. Nov 2018;29(11):1689-1695. doi:10.1007/s00192-018-3731-2

Joint report on terminology for surgical procedures to treat pelvic organ prolapse. *International urogynecology journal*. Feb 10 2020;doi:10.1007/s00192-020-04236-1

Kapoor S, Sivanesan K, Robertson JA, Veerasingham M, Kapoor V. Sacrospinous hysteropexy: review and meta-analysis of outcomes. *International urogynecology journal*. Sep 2017;28(9):1285-1294. doi:10.1007/s00192-017-3291-x

Maher C, Feiner B, Baessler K, Christmann-Schmid C, Haya N, Brown J. Surgery for women with apical vaginal prolapse. *The Cochrane database of systematic reviews*. Oct 1 2016;10:CD012376. doi:10.1002/14651858.cd012376

Maher C, Yeung E, Haya N, Christmann-Schmid C, Mowat A, Chen Z, Baessler K. Surgery for women with apical vaginal prolapse. *Cochrane Database Syst Rev*. 2023 Jul 26;7(7):CD012376. doi: 10.1002/14651858.CD012376.pub2.

Maher C, Yeung E, Haya N, Christmann-Schmid C, Mowat A, Chen Z, Baessler K. Surgery for women with apical vaginal prolapse. *Cochrane Database Syst Rev*. 2023 Jul 26;7(7):CD012376. doi: 10.1002/14651858.CD012376.pub2.

Detollenaere RJ, den Boon J, Stekelenburg J, et al. Sacrospinous hysteropexy versus vaginal hysterectomy with suspension of the uterosacral ligaments in women with uterine prolapse stage 2 or higher: multicentre randomised non-inferiority trial. *BMJ (Clinical research ed)*. Jul 23 2015;351:h3717. doi:10.1136/bmj.h3717

Husby K, Lose G, Kopp TI, Hall Viborg P, Kesmodel US, Klarskov N. The manchester-fothergill procedure versus vaginal hysterectomy in the treatment of uterine prolapse: A matched cohort study. Conference Abstract. *International urogynecology journal*. June 2017;28 (1 Supplement 1):S3-S4.

Husby KR, Tolstrup CK, Lose G, Klarskov N. Manchester-Fothergill procedure versus vaginal hysterectomy with uterosacral ligament suspension: an activity-based costing analysis. *International urogynecology journal*. 2018;29(8):1161-1171. doi:10.1007/s00192-018-3575-9

Enklaar RA, Schulten SFM, van Eijndhoven HWF, Weemhoff M, van Leijsen SAL, van der Weide MC, van Bavel J, Verkleij-Hagoort AC, Adang EMM, Kluivers KB; SAM Study Group. Manchester Procedure vs Sacrospinous Hysteropexy for Treatment of Uterine Descent: A Randomized Clinical Trial. *JAMA*. 2023 Aug 15;330(7):626-635. doi: 10.1001/jama.2023.13140. Erratum in: *JAMA*. 2023 Sep 19;330(11):1101. doi: 10.1001/jama.2023.17655.